Stock listing
NASDAQ:BBOT BridgeBio Oncology Therapeutics, Inc. Stock
Home listing (NASDAQ) of BridgeBio Oncology Therapeutics, Inc.
Follow BridgeBio Oncology Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BBOT
$2.31 USD -0.31 (-11.8%)
Close on Nov 2, 2026
- Day range
- $2.30 – $2.64 USDNov 2, 2026
- Volume
- 579,578 sharesNov 2, 2026
- Market cap
- $185.2M USDAt the close on Nov 2, 2026 · price × 80.17M shares outstanding
- 52-week range
- $2.30 – $14.87 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $2.67M USDMedian day 473,900 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BBOT · Home | $2.31 USD | -0.31 (-11.8%) | 579,578 | $2.64 | $2.64 | $2.295 | $2.62 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:BBOT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.31 | -0.31 | -11.8% | $2.64 | $2.64 | $2.295 | 579,578 | |
| $2.62 | -0.08 | -3.0% | $2.70 | $2.74 | $2.605 | 314,785 | |
| $2.70 | -0.10 | -3.6% | $2.81 | $2.948 | $2.69 | 357,036 | |
| $2.80 | +0.11 | +4.1% | $2.67 | $2.855 | $2.61 | 482,179 | |
| $2.69 | +0.05 | +1.9% | $2.65 | $2.725 | $2.51 | 1,755,926 | |
| $2.64 | -0.02 | -0.8% | $2.66 | $2.68 | $2.61 | 483,080 | |
| $2.66 | -0.19 | -6.7% | $2.83 | $2.83 | $2.60 | 737,317 | |
| $2.85 | +0.17 | +6.3% | $2.66 | $2.85 | $2.66 | 661,895 | |
| $2.68 | -0.04 | -1.5% | $2.71 | $2.855 | $2.66 | 942,242 | |
| $2.72 | -0.13 | -4.6% | $2.85 | $2.98 | $2.70 | 660,932 | |
| $2.85 | +0.03 | +1.1% | $2.84 | $2.90 | $2.79 | 695,643 | |
| $2.82 | -0.13 | -4.4% | $2.95 | $2.95 | $2.81 | 480,800 | |
| $2.95 | +0.045 | +1.5% | $2.90 | $3.304 | $2.86 | 473,900 | |
| $2.905 | -0.045 | -1.5% | $2.94 | $3.07 | $2.88 | 440,600 | |
| $2.95 | -0.31 | -9.5% | $3.24 | $3.34 | $2.93 | 505,700 | |
| $3.26 | -0.05 | -1.5% | $3.31 | $3.37 | $3.23 | 234,000 | |
| $3.31 | -0.11 | -3.2% | $3.43 | $3.50 | $3.295 | 472,000 | |
| $3.42 | -0.02 | -0.6% | $3.43 | $3.43 | $3.27 | 566,200 | |
| $3.44 | -0.06 | -1.7% | $3.46 | $3.57 | $3.36 | 321,300 | |
| $3.50 | -0.10 | -2.8% | $3.60 | $3.72 | $3.48 | 659,700 | |
| $3.60 | -0.29 | -7.5% | $3.88 | $3.88 | $3.575 | 481,600 | |
| $3.89 | -0.05 | -1.3% | $3.97 | $4.045 | $3.88 | 486,000 | |
| $3.94 | -0.16 | -3.9% | $4.05 | $4.10 | $3.82 | 1,363,700 | |
| $4.10 | +0.18 | +4.6% | $3.94 | $4.15 | $3.875 | 736,300 | |
| $3.92 | +0.11 | +2.9% | $3.83 | $4.02 | $3.80 | 537,400 | |
| $3.81 | -0.14 | -3.5% | $3.91 | $3.925 | $3.79 | 476,600 | |
| $3.95 | -0.04 | -1.0% | $4.00 | $4.00 | $3.89 | 523,500 | |
| $3.99 | -0.17 | -4.1% | $4.15 | $4.17 | $3.90 | 656,600 | |
| $4.16 | -0.50 | -10.7% | $4.61 | $4.70 | $4.05 | 539,600 | |
| $4.66 | 0.00 | 0.0% | $4.63 | $4.81 | $4.60 | 509,100 | |
| $4.66 | -0.11 | -2.3% | $4.84 | $4.84 | $4.594 | 468,700 | |
| $4.77 | -0.12 | -2.5% | $4.86 | $4.86 | $4.69 | 1,229,800 | |
| $4.89 | +0.13 | +2.7% | $4.84 | $5.10 | $4.84 | 415,400 | |
| $4.76 | -0.12 | -2.5% | $4.93 | $4.99 | $4.71 | 855,300 | |
| $4.88 | -0.17 | -3.4% | $5.01 | $5.015 | $4.72 | 629,200 | |
| $5.05 | +0.10 | +2.0% | $4.91 | $5.18 | $4.85 | 956,000 | |
| $4.95 | -0.57 | -10.3% | $5.53 | $5.616 | $4.90 | 1,630,900 | |
| $5.52 | -1.235 | -18.3% | $6.785 | $6.785 | $5.48 | 2,789,400 | |
| $6.755 | -2.105 | -23.8% | $8.86 | $8.86 | $6.295 | 1,498,900 | |
| $8.86 | -0.12 | -1.3% | $8.88 | $9.05 | $8.775 | 152,500 | |
| $8.98 | +0.08 | +0.9% | $8.80 | $9.06 | $8.65 | 117,600 | |
| $8.90 | +0.01 | +0.1% | $8.93 | $9.041 | $8.66 | 139,200 | |
| $8.89 | +0.07 | +0.8% | $8.81 | $9.185 | $8.73 | 238,900 | |
| $8.82 | +0.02 | +0.2% | $8.70 | $8.90 | $8.535 | 145,600 | |
| $8.80 | +0.06 | +0.7% | $8.72 | $9.195 | $8.41 | 476,000 | |
| $8.74 | -0.44 | -4.8% | $9.16 | $9.16 | $8.69 | 195,000 | |
| $9.18 | -0.08 | -0.9% | $9.19 | $9.315 | $9.06 | 385,300 | |
| $9.26 | -0.11 | -1.2% | $9.36 | $9.47 | $9.04 | 247,200 | |
| $9.37 | +0.23 | +2.5% | $9.24 | $9.473 | $9.18 | 197,974 | |
| $9.14 | +0.06 | +0.7% | $9.10 | $9.358 | $8.80 | 338,518 | |
| $9.08 | 0.00 | 0.0% | $9.19 | $9.435 | $9.03 | 170,900 | |
| $9.08 | -0.52 | -5.4% | $9.55 | $9.78 | $9.08 | 203,300 | |
| $9.60 | +0.65 | +7.3% | $9.16 | $9.72 | $9.14 | 414,300 | |
| $8.95 | -0.09 | -1.0% | $9.02 | $9.125 | $8.82 | 446,900 | |
| $9.04 | -0.02 | -0.2% | $8.90 | $9.40 | $8.90 | 249,900 | |
| $9.06 | -0.17 | -1.8% | $9.22 | $9.49 | $8.80 | 227,500 | |
| $9.23 | -0.19 | -2.0% | $9.48 | $9.61 | $9.20 | 303,800 | |
| $9.42 | +0.22 | +2.4% | $9.07 | $9.46 | $9.00 | 150,500 | |
| $9.20 | -0.08 | -0.9% | $9.33 | $9.44 | $9.095 | 202,000 | |
| $9.28 | -0.05 | -0.5% | $9.30 | $9.62 | $9.24 | 208,900 | |
| $9.33 | +0.55 | +6.3% | $8.91 | $9.42 | $8.89 | 219,400 | |
| $8.78 | -0.18 | -2.0% | $8.98 | $9.31 | $8.75 | 187,000 | |
| $8.96 | +0.09 | +1.0% | $8.83 | $9.02 | $8.76 | 147,400 | |
| $8.87 | +0.62 | +7.5% | $8.27 | $8.87 | $8.225 | 507,100 | |
| $8.25 | +0.16 | +2.0% | $8.14 | $8.47 | $8.00 | 210,100 |
- Ticker
- NASDAQ:BBOT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 12, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 35 slides
Latest news
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 12, 2026
Closed $2.95 (-9.5%) on Oct 13, 2026
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
Sep 8, 2026
Closed $6.76 (-23.8%) on Sep 9, 2026
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Aug 11, 2026
Closed $9.42 (+2.4%) on Aug 12, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
Closed $8.08 (-0.6%) on May 13, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Apr 22, 2026
Closed $8.97 (+1.1%) on Apr 23, 2026
BBOT Presents Preclinical Data Showing RAS: PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
Apr 21, 2026
Closed $8.87 (-6.2%) on Apr 22, 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Apr 20, 2026
Closed $9.46 (+2.2%) on Apr 21, 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Mar 18, 2026
Closed $9.05 (+1.9%) on Mar 19, 2026
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
Mar 6, 2026
Closed $10.42 (+5.4%) on Mar 6, 2026
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Mar 5, 2026
Closed $10.42 (+5.4%) on Mar 6, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 35 slides · September 2026
SPAC Merger (February 2025)
SPAC merger · 50 slides · Feb 28, 2025
ENA 2024
Conference · 19 slides · 2024
Technical Presentation (September 2023)
Technical · 30 slides · September 2023
BridgeBio Oncology Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 26 in all · newest Oct 12, 2026 · oldest 2025
- Decks
- 5 decks · latest September 2026
Where BridgeBio Oncology Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BBOT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BBOT | BOATS | United States | USD |
| BIVA:BBOT | BIVA | Mexico | MXN |
| BMV:BBOT | BMV | Mexico | MXN |
Log in to ask 6ix AI your own questions about BridgeBio Oncology Therapeutics, Inc.